Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Effectiveness and Safety of Mlc601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial Publisher



Pakdaman H1 ; Harandi AA1 ; Hatamian H3 ; Tabatabae M2 ; Kasmaei HD1 ; Ghassemi A4 ; Gharagozli K1 ; Ashrafi F1 ; Naeini PE5 ; Tavakolian M1 ; Shahin D1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neurology, Shahid Beheshti University of Medical Sciences, Velenjak Street, Tehran, 4739, Iran
  2. 2. Social Security, Tehran, Iran
  3. 3. Department of Neurology, Rasht University of Medical Sciences, Rasht, Iran
  4. 4. Social Security, Kerman, Iran
  5. 5. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Dementia and Geriatric Cognitive Disorders Extra Published:2015


Abstract

Background: MLC601 is a possible modulator of amyloid precursor protein processing, and in a clinical trial study MLC601 showed some effectiveness in cognitive function in Alzheimer's disease (AD) patients. We aimed to evaluate the effectiveness and safety of MLC601 in the treatment of mild to moderate AD as compared to 3 approved cholinesterase inhibitors (ChEIs) including donepezil, rivastigmine and galantamine. Methods: In a multicenter, nonblinded, randomized controlled trial, 264 volunteers with AD were randomly divided into 4 groups of 66; groups 1, 2, 3 and 4 received donepezil, rivastigmine, MLC601 and galantamine, respectively. Subjects underwent a clinical diagnostic interview and a cognitive/functional battery including the Mini-Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog). Patients were visited every 4 months, and the score of cognition was recorded by the neurologists. Results: There were no significant differences in age, sex, marital status and baseline score of cognition among the 4 groups. In total, 39 patients (14.7%) left the study. Trend of cognition changes based on the modifications over the time for MMSE and ADAS-cog scores did not differ significantly among groups (p = 0.92 for MMSE and p = 0.87 for ADAS-Cog). Conclusion: MLC601 showed a promising safety profile and also efficacy compared to 3 FDA-approved ChEIs. © 2015 S. Karger AG, Basel.
Related Docs
View other Related Docs
1. A Comprehensive Investigation of the Associations Between Tensor-Based Morphometry Indices and Executive Functions, Memory, Language, and Visuospatial Abilities in Patients in the Alzheimer's Disease Continuum, Clinical Neurology and Neurosurgery (2024)
2. Csf-Targeted Proteomics Indicate Amyloid-Beta Ratios in Patients With Alzheimer's Dementia Spectrum, International Journal of Alzheimer's Disease (2023)
3. Uncovering Cerebral Blood Flow Patterns Corresponding to Amyloid-Beta Accumulations in Patients Across the Alzheimer’S Disease Continuum Using the Arterial Spin Labeling, Neurological Sciences (2025)
4. Pharmacological Activities and Molecular Mechanisms of Sinapic Acid in Neurological Disorders, ACS Chemical Neuroscience (2024)
5. Effects of Hydroalcoholic, Methanolic, and Hexane Extracts of Brown Algae Sargassum Angustifolium on Scopolamine-Induced Memory Impairment and Learning Deficit in Rodents, Research in Pharmaceutical Sciences (2023)
6. New Drugs for Alzheimer’S Disease: Aducanumab or Donanemab?, Physiology and Pharmacology (Iran) (2024)
7. The Effect of the Mediterranean Diet on Cognitive Function in Patients With Parkinson's Disease: A Randomized Clinical Controlled Trial, Complementary Therapies in Medicine (2020)
8. Neutrophil to Lymphocyte Ratio in Alzheimer’S Disease: A Systematic Review and Meta-Analysis, PLoS ONE (2024)
Experts (# of related papers)
View all Related Experts
Ahmad Chitsaz (3)
Mohammad Rabbani (3)
Other Related Docs
9. Evaluation of the Effect of Donepezil on Cerebral Blood Flow Velocity in Alzheimer's Disease, Neurosciences (2010)
10. Evaluation and Estimation of Gray Matter Volume Using Voxel-Based Morphometry of the Brain Magnetic Resonance Imaging (Mri) in Normal Elderly People and Those With Mild Cognitive Impairment, Journal of Isfahan Medical School (2015)
11. Association of Metabolic Dysfunction With Cognitive Decline and Alzheimer's Disease: A Review of Metabolomic Evidence, Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024)
12. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Pregabalin Efficacy in the Treatment of Behavioral and Psychological Symptoms of Dementia in Patients With Alzheimer’S Disease, Frontiers in Neuroscience (2024)
13. Evaluation the Effect of Donepezil on Cerebral Blood Flow Velocity in Alzheimer's Disease, Journal of Isfahan Medical School (2010)
14. Effects of Extracts and Manna of Echinops Cephalotes on Impaired Cognitive Function Induced by Scopolamine in Mice, Research in Pharmaceutical Sciences (2024)
15. P-Tau231 As a Diagnostic Biomarker for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis, Annals of Indian Academy of Neurology (2022)
16. Transfer Learning and Neural Network-Based Approach on Structural Mri Data for Prediction and Classification of Alzheimer’S Disease, Diagnostics (2025)
17. The Relationship Between Regional Brain Volumes and the Extent of Coronary Artery Disease in Mild Cognitive Impairment, Journal of Research in Medical Sciences (2014)
18. Effects of Piper Nigrum Fruit and Cinnamum Zeylanicum Bark Alcoholic Extracts, Alone and in Combination, on Scopolamine-Induced Memory Impairment in Mice, Research in Pharmaceutical Sciences (2021)
19. Novel Effects of Rosa Damascena Extract on Patients With Neurocognitive Disorder and Depression: A Clinical Trial Study, International Journal of Preventive Medicine (2018)
20. The Role of Inflammatory Mediators in the Pathogenesis of Alzheimer’S Disease, Sultan Qaboos University Medical Journal (2015)
21. Which Neuroimaging and Fluid Biomarkers Method Is Better in Theranostic of Alzheimer's Disease? an Umbrella Review, IBRO Neuroscience Reports (2024)